Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cerilliant
US Department of Justice
Julphar
Argus Health
Cantor Fitzgerald
Fish and Richardson
Healthtrust
Express Scripts

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020234

« Back to Dashboard

NDA 020234 describes TEGRETOL-XR, which is a drug marketed by Novartis and is included in one NDA. It is available from six suppliers. Additional details are available on the TEGRETOL-XR profile page.

The generic ingredient in TEGRETOL-XR is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
Summary for 020234
Tradename:TEGRETOL-XR
Applicant:Novartis
Ingredient:carbamazepine
Patents:0
Therapeutic Class:Anticonvulsants
Bipolar Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 020234
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234 NDA Novartis Pharmaceuticals Corporation 0078-0510 N 0078-0510-05
TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234 NDA Novartis Pharmaceuticals Corporation 0078-0511 N 0078-0511-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Mar 25, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength200MG
Approval Date:Mar 25, 1996TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength400MG
Approval Date:Mar 25, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020234

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-002 Mar 25, 1996 ➤ Sign Up ➤ Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-001 Mar 25, 1996 ➤ Sign Up ➤ Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-003 Mar 25, 1996 ➤ Sign Up ➤ Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-003 Mar 25, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Deloitte
Medtronic
Dow
Queensland Health
Fuji
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.